Hepato-renal Syndrome: Etiopathogenesis, Diagnosis and Treatment

1. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001;49(5): 729-37.10.1136/gut.49.5.729Search in Google Scholar

2. Arroyo V, Torre A, Guevara M. Recent advances in hepatorenal syndrome. Trop Gastroenterol 2005; 26(1): 13-20.Search in Google Scholar

3. Barada K. Hepatorenal syndrome: pathogenesis and novel pharmacological targets. Curr Opin Pharmacol 2004; 4(2):189-97.10.1016/j.coph.2003.10.007Search in Google Scholar

4. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122(6): 1658-76.10.1053/gast.2002.33575Search in Google Scholar

5. Blaise P, Moonen M, Rorive G. Update on hepatorenal syndrome. Nephrologie 2002; 23(1): 11-7. (French)Search in Google Scholar

6. Kramer L, Horl WH. Hepatorenal syndrome. Semin Nephrol 2002; 22(4): 290-301.10.1053/snep.2002.33670Search in Google Scholar

7. Biswas KD, Jain AK. Hepatorenal syndrome. Review.Tropical Gastroenterology 2002; 23(3):113-6.Search in Google Scholar

8. Gentilini P, Vizzutti F, Gentilini A, Zipoli M, Foschi M, Romanelli RG. Update on ascites and hepatorenal syndrome. Review. Digestive & Liver Disease 2002; 34(8):592-605.10.1016/S1590-8658(02)80094-9Search in Google Scholar

9. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164-76.10.1002/hep.510230122Search in Google Scholar

10. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, Navasa M, Claria J, Rimola A, Arroyo V. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229-236.10.1016/0016-5085(93)90031-7Search in Google Scholar

11. Garcia-Tsao G, Parikh CR, Viola A: Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-2077.10.1002/hep.22605Search in Google Scholar

12. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362(9398): 1819-27.10.1016/S0140-6736(03)14903-3Search in Google Scholar

13. Cholongitas E, Senzolo M, Patch D, Shaw S, O’Beirne J, Burroughs AK: Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol 2009; 21: 744-750.10.1097/MEG.0b013e328308bb9c20160527Search in Google Scholar

14. Gines P: Pharmacological management of hepatorenal syndrome: lessons from non-responders. J Hepatol 2011; 55: 268-269.10.1016/j.jhep.2011.02.00621349296Search in Google Scholar

15. Gluud LL, Christensen K, Christensen E, Krag A: Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-584.10.1002/hep.2328619885875Search in Google Scholar

16. Petrović D.Hepato-renalni sindrom: etiopatogeneza, dijagnostika I lečenje. U: Akutno oštećenje bubrega u kliničkoj praksi. Petrović D.Ed.Kragujevac:Interprint 2013:277-84Search in Google Scholar

17. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56: 1310-1318.Search in Google Scholar

18. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, Rodes J, Gines P: Meld score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41: 1282-1289.10.1002/hep.2068715834937Search in Google Scholar

19. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003;16:233-243.10.1053/jhep.2003.5008412540770Search in Google Scholar

20. Angeli P, Morando F, Cavallin M, Piano S. Hepatorenal syndrome. Contrib Nephrol. 2011;174:46-55.10.1159/00032923521921608Search in Google Scholar

21. Cardenas A, Gines P, Rodes J. Renal complications. In: Schiff ER, Sorrekk MF, Maddrey WC, editors. Schiff ’s Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins: A Wolters Kluwer Company; 2003. p.497-509Search in Google Scholar

22. Petrović D.Akutno oštećenje bubrega; etiologija, dijagnostika i lečenje. Medicinska istraživanja 2011; 45(3):7-13Search in Google Scholar

23. Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, Bellomo R, Genyk Y. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative Group. Crit Care. 2012;16:R23.10.1186/cc11188339626722322077Search in Google Scholar

24. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;16:1279-1290.10.1056/NEJMra080913919776409Search in Google Scholar

25. Angeli P, Wong F, Watson H. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44:1535-1542.10.1002/hep.2141217133458Search in Google Scholar

26. Sherlock S, Dooley J. Ascites. In: Sherlock S, Dooley J, editors. Diseases of the Liver and Biliary System. 11th ed. Oxford, UK: Blackwell Publishing Company; 2002. p.127-46.10.1002/9780470986820Search in Google Scholar

27. Gines P, Berl T, Bernardi M. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998;28:851-86410.1002/hep.5102803379731583Search in Google Scholar

28. Amodio P, Del Piccolo F, Petteno E. Prevalence and prognostic value of quantified electroencephalogram alterations in cirrhotic patients. J Hepatol. 2001;35:37-45.10.1016/S0168-8278(01)00129-5Search in Google Scholar

29. Heuman DM, Abou-Assi SG, Habib A. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40:802-810.10.1002/hep.1840400409Search in Google Scholar

30. Konstam MA, Ghiorghiade M, Burnett JC Jr. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. LAMA 2007;297:1319-1331.10.1001/jama.297.12.131917384437Search in Google Scholar

31. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz del Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.10.1056/NEJM19990805341060310432325Search in Google Scholar

32. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features.Hepatology 2007;45:223-229.10.1002/hep.2144317187409Search in Google Scholar

33. Lukić S, Petrović D. Prevencija akutnog oštećenja bubrega u jedinicama intenzivnog lečenja. Med Čas 2012; 46(2):100-4.Search in Google Scholar

34. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients.Transplantation 1991;51:428-430.10.1097/00007890-199102000-000301994538Search in Google Scholar

35. Lafayette RA, Pare G, Schmid CH, King AJ, Rohrer RJ, Nasraway SA. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol. 1997;48:159-164. Search in Google Scholar

36. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation. 1995;59:361-365.10.1097/00007890-199502150-00010Search in Google Scholar

37. Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006;26:834-839.10.1111/j.1478-3231.2006.01302.x16911466Search in Google Scholar

38. Olivera-Martinez M, Sayles H, Vivekanandan R, D’ Souza S, Florescu MC. Hepatorenal syndrome: are we missing some prognostic factors? Dig Dis Sci 2012 57(1):210-4.10.1007/s10620-011-1861-121850494Search in Google Scholar

39. Le Moine O. Hepatorenal syndrome - outcome after liver transplantation. Nephrol Dial Transplant 1998; 13(1):20-2.10.1093/ndt/13.1.209481708Search in Google Scholar

40. Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, Zanus G, Cillo U, Gatta A, Angeli P. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation? J Hepatol. 2011;55:491-496.Search in Google Scholar

41. Caraceni P, Santi L, Mirici F, Montanari G, Bevilacqua V, Pinna AD, Bernardi M. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.Dig Liver Dis. 2011;43:242-24510.1016/j.dld.2010.08.001Search in Google Scholar

42. Salo J, Gines A, Quer JC, Fernandez-Esparrach G, Guevara M, Gines P, Bataller R, Planas R, Jimenez W, Arroyo V, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996;25:916-923.10.1016/S0168-8278(96)80297-2Search in Google Scholar

43. European Association for the Study of the Liver: EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.10.1016/j.jhep.2010.05.00420633946Search in Google Scholar

44. Runyon BA: Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107.10.1002/hep.2285319475696Search in Google Scholar

45. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006;43:385-394.10.1002/hep.2109416496352Search in Google Scholar

46. Maddukuri G, Cai CX, Munigala S, Mohammadi F, Zhang Z. Targeting an Early and Substantial Increase in Mean Arterial Pressure Is Critical in the Management of Type 1 Hepatorenal Syndrome: A Combined Retrospective and Pilot Study.Dig Dis Sci 2013.10.1007/s10620-013-2899-z24146317Search in Google Scholar

47. Martin L, Lahi M, Pepin MN, Guevara M, et al. Terlipressin and albumina vs albumina in patients with cirrhosis and hepatorenal syndrome: a randomized study.Gastroenterology 2008;134:1352-1359.10.1053/j.gastro.2008.02.02418471512Search in Google Scholar

48. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;47:401-404.10.1097/00042737-200212000-0001312468959Search in Google Scholar

49. Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: Evidence for present indications. J Gastroenterol Hepatol. 2011;26 Suppl 1:109-114.10.1111/j.1440-1746.2010.06583.x21199521Search in Google Scholar

50. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64.10.1002/hep.2026215239086Search in Google Scholar

51. Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010;59:988-1000.10.1136/gut.2009.19322720581246Search in Google Scholar

52. Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, Ardizzone G, Valente U. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003;50:1753-1755. Search in Google Scholar